vs
Side-by-side financial comparison of Hologic (HOLX) and SCANSOURCE, INC. (SCSC). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $766.5M, roughly 1.4× SCANSOURCE, INC.). Hologic runs the higher net margin — 17.1% vs 2.2%, a 14.9% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $28.9M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs 0.9%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
ScanSource, Inc. is a leading global specialty technology distributor offering a broad portfolio of solutions including point-of-sale systems, barcode scanning tools, cybersecurity products, cloud services and communication solutions. It primarily serves value-added resellers, managed service providers and enterprise clients across North America, Latin America and Europe, covering retail, healthcare, industrial and public sector core segments.
HOLX vs SCSC — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $766.5M |
| Net Profit | $179.1M | $16.5M |
| Gross Margin | 56.0% | 13.4% |
| Operating Margin | 22.6% | 2.3% |
| Net Margin | 17.1% | 2.2% |
| Revenue YoY | 2.5% | 2.5% |
| Net Profit YoY | -10.9% | -3.3% |
| EPS (diluted) | $0.79 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $766.5M | ||
| Q3 25 | $1.0B | $739.6M | ||
| Q2 25 | $1.0B | $812.9M | ||
| Q1 25 | $1.0B | $704.8M | ||
| Q4 24 | $1.0B | $747.5M | ||
| Q3 24 | $988.0M | $775.6M | ||
| Q2 24 | $1.0B | $746.1M | ||
| Q1 24 | $1.0B | $752.6M |
| Q4 25 | $179.1M | $16.5M | ||
| Q3 25 | $187.2M | $19.9M | ||
| Q2 25 | $194.9M | $20.1M | ||
| Q1 25 | $-17.4M | $17.4M | ||
| Q4 24 | $201.0M | $17.1M | ||
| Q3 24 | $178.6M | $17.0M | ||
| Q2 24 | $194.5M | $16.1M | ||
| Q1 24 | $169.9M | $12.8M |
| Q4 25 | 56.0% | 13.4% | ||
| Q3 25 | 55.6% | 14.5% | ||
| Q2 25 | 56.3% | 12.9% | ||
| Q1 25 | 37.5% | 14.2% | ||
| Q4 24 | 56.8% | 13.6% | ||
| Q3 24 | 56.4% | 13.1% | ||
| Q2 24 | 55.4% | 13.0% | ||
| Q1 24 | 53.3% | 12.6% |
| Q4 25 | 22.6% | 2.3% | ||
| Q3 25 | 22.6% | 3.5% | ||
| Q2 25 | 24.9% | 3.3% | ||
| Q1 25 | -0.7% | 3.2% | ||
| Q4 24 | 22.5% | 2.5% | ||
| Q3 24 | 23.3% | 2.3% | ||
| Q2 24 | 24.1% | 2.9% | ||
| Q1 24 | 20.7% | 2.3% |
| Q4 25 | 17.1% | 2.2% | ||
| Q3 25 | 17.8% | 2.7% | ||
| Q2 25 | 19.0% | 2.5% | ||
| Q1 25 | -1.7% | 2.5% | ||
| Q4 24 | 19.7% | 2.3% | ||
| Q3 24 | 18.1% | 2.2% | ||
| Q2 24 | 19.2% | 2.2% | ||
| Q1 24 | 16.7% | 1.7% |
| Q4 25 | $0.79 | $0.75 | ||
| Q3 25 | $0.84 | $0.89 | ||
| Q2 25 | $0.86 | $0.87 | ||
| Q1 25 | $-0.08 | $0.74 | ||
| Q4 24 | $0.87 | $0.70 | ||
| Q3 24 | $0.75 | $0.69 | ||
| Q2 24 | $0.82 | $0.66 | ||
| Q1 24 | $0.72 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $83.5M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $910.9M |
| Total Assets | $9.2B | $1.7B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $83.5M | ||
| Q3 25 | $2.2B | $124.9M | ||
| Q2 25 | $1.9B | $126.2M | ||
| Q1 25 | $1.6B | $146.3M | ||
| Q4 24 | $2.0B | $110.5M | ||
| Q3 24 | $2.3B | $145.0M | ||
| Q2 24 | $2.4B | $185.5M | ||
| Q1 24 | $2.2B | $159.1M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | $910.9M | ||
| Q3 25 | $5.0B | $914.0M | ||
| Q2 25 | $4.8B | $906.4M | ||
| Q1 25 | $4.6B | $901.7M | ||
| Q4 24 | $4.8B | $900.7M | ||
| Q3 24 | $5.1B | $920.9M | ||
| Q2 24 | $5.0B | $924.3M | ||
| Q1 24 | $4.8B | $944.1M |
| Q4 25 | $9.2B | $1.7B | ||
| Q3 25 | $9.0B | $1.7B | ||
| Q2 25 | $8.8B | $1.8B | ||
| Q1 25 | $8.5B | $1.7B | ||
| Q4 24 | $8.7B | $1.7B | ||
| Q3 24 | $9.2B | $1.8B | ||
| Q2 24 | $8.9B | $1.8B | ||
| Q1 24 | $8.7B | $1.8B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $30.8M |
| Free Cash FlowOCF − Capex | $215.2M | $28.9M |
| FCF MarginFCF / Revenue | 20.5% | 3.8% |
| Capex IntensityCapex / Revenue | 1.4% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.28× | 1.87× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $30.8M | ||
| Q3 25 | $355.1M | $23.2M | ||
| Q2 25 | $343.3M | — | ||
| Q1 25 | $169.4M | $66.1M | ||
| Q4 24 | $189.3M | $-6.2M | ||
| Q3 24 | $367.0M | $44.8M | ||
| Q2 24 | $405.8M | — | ||
| Q1 24 | $292.4M | $160.2M |
| Q4 25 | $215.2M | $28.9M | ||
| Q3 25 | $341.4M | $20.8M | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | $64.6M | ||
| Q4 24 | $172.5M | $-8.2M | ||
| Q3 24 | $350.6M | $42.5M | ||
| Q2 24 | $385.3M | — | ||
| Q1 24 | $279.6M | $157.7M |
| Q4 25 | 20.5% | 3.8% | ||
| Q3 25 | 32.5% | 2.8% | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | 9.2% | ||
| Q4 24 | 16.9% | -1.1% | ||
| Q3 24 | 35.5% | 5.5% | ||
| Q2 24 | 38.1% | — | ||
| Q1 24 | 27.5% | 21.0% |
| Q4 25 | 1.4% | 0.3% | ||
| Q3 25 | 1.3% | 0.3% | ||
| Q2 25 | 1.3% | 0.3% | ||
| Q1 25 | 1.5% | 0.2% | ||
| Q4 24 | 1.6% | 0.3% | ||
| Q3 24 | 1.7% | 0.3% | ||
| Q2 24 | 2.0% | 0.2% | ||
| Q1 24 | 1.3% | 0.3% |
| Q4 25 | 1.28× | 1.87× | ||
| Q3 25 | 1.90× | 1.17× | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | 3.79× | ||
| Q4 24 | 0.94× | -0.36× | ||
| Q3 24 | 2.05× | 2.64× | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | 12.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
